Navigation Links
Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients

SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2006, and the quarterly report on Form 10-Q for the quarter ended January 31, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


Contacts:
GendeLLindheim BioCom Partners
Investors Media
info@peregrineinc.com Barbara Lindheim
(800) 987-8256 (212) 918-4650


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
2. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/23/2008)... publication in July print edition of Clinical ...DIANAPOLIS, July 23 /- A Roche Diagno...N-terminal pro-B-type natriuretic peptide,(NT-proB...risk,stratification in predicting the risk of card...ted with non-steroidal anti-inflammatory drugs of,...
(Date:7/23/2008)...3 /- InCode BioPharmaceutics, Inc.,a...ced preclinical test,results demonstrating the uti...eatment of the rare chronic blood disorder paroxys...esults will be presented at the XXII,International...ber 28,2008., The only treatment currently avail...
(Date:7/22/2008).../- Nonin Medical, a leading innovator...an 20 years, has entered,the clinical testing phas...onal oxygen saturation. Today,s most common applic...ring of the regional blood oxygenation,in the brai...utcomes from an ongoing clinical study at the,Duke...
(Date:7/22/2008)... Lantus(R) and Apidra(R) Resulted in Significant, ..., Whatever the Algorithm ...ire/ -- Results from the "Adjust to,Target in Type...arbohydrate,Counting for Adjustment of Mealtime In...ican Diabetes Association,s (ADA) medical journal,...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Almost Family Announces Expansion of Revolving Credit Facility 7573 1Almost Family Announces Expansion of Revolving Credit Facility 7573 2Almost Family Announces Expansion of Revolving Credit Facility 7573 3Capital BlueCross HMO Plan is Ranked No 1 in Pennsylvania for Member Satisfaction 7571 1Capital BlueCross HMO Plan is Ranked No 1 in Pennsylvania for Member Satisfaction 7571 27 or 8 Hours of Sleep Best for Health 7569 1Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2067 1Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2067 2
...earch and Treatment of Rare but Devastating,Condit...ry University London,and the University of Leicest...ntial breakthrough in the treatment of a rare but,...dren and young,people. , In a world first, the cli...ave already treated one patient with promising,res...
...tner Forest Laboratories, Inc. Today,Announced the...cute,Ischemic Stroke) Study with the Compound Desm...N AG (Frankfurt Stock,Exchange, Prime Standard: PA...YSE: FRX) today announced topline results of,the D...y with the,compound Desmoteplase. The Phase III st...
Other Medicine Technology:World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... location for clinical trials for many pharmaceuti...s Squibb, GlaxoSmithkline, Eli Lilly are among tho...y. Currently over 226 clinical trials approved by...nd Drug Administration (FDA) are in India. Faced...
...hospital mortality is on the high during weekends.... not matching with the inflow// of the patients. T...is team from the University of Medicine and Dentis...ostis studied 231,164 patients who were admitted t...
...olysed casein proteins reduced the development of ...rom Germany. "The 3-year results of this large-sc...learly confirm the concept that the risk for [atop...thma can be reduced by nutritional intervention in...
...wn as "eSie Touch Elasticity Imaging" will be show...ropean Congress of Radiology) in Vienna//, Austria...n adjunct to regular breast ultrasound examination...ion of benign and malignant tissue. The method is ...
Other Medicine News:Health News:India Fast Become Prime Location for Clinical Trials, but Vigilance Called for 2Health News:Hydrolysed Casein Formula may Slash Eczema in Infants 2Health News:eSie Touch Elasticity Imaging, and a Promise of Avoiding Breast Biopsies 2
SUR-FIT Natura® Urostomy Pouch
New Image Urostomy Pouch, Beige
New Image Sterile Drainable Kits with Lock 'n Roll
New Image Pre-sized Flextend Skin Barrier, Floating Flange, with Tape
Medicine Products: